Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142).

被引：5
|
作者：
Eads, Jennifer Rachel
Catalano, Paul J.
Fisher, George A.
Klimstra, David S.
Zhang, Zheng
Rubin, Daniel
Iagaru, Andrei
Wong, Terence Z.
O'Dwyer, Peter J.
机构：
[1] Case Western Reserve Univ, Univ Hosp, Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Brown Univ, Providence, RI 02912 USA
[6] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[7] Univ N Carolina, Chapel Hill, NC USA
[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4149
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): A randomized phase II Hellenic Oncology Research Group trial
    Karampeazis, A.
    Vamvakas, L.
    Agelidou, A.
    Chandrinos, V.
    Tsiafaki, X.
    Christophylakis, C.
    Chainis, K.
    Kakolyris, S.
    Kalykaki, A.
    Mavroudis, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)
    Saba, N. F.
    Flamand, Y.
    Lin, D. T.
    Chung, C. H.
    McDonald, M. W.
    Flampouri, S.
    Khan, S. A.
    Snyderman, C. H.
    Hanna, E.
    El-Sayed, Y. H.
    Solares, C. A.
    Duan, F.
    Ho, A. L.
    Samuels, M. A.
    Swiecicki, P. L.
    Subramaniam, R. M.
    Chakravarthy, A.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S614 - S614
  • [23] A phase II study of erlotinib (E) in previously untreated elderly patients (pts) with inoperable or advanced stage non-small cell lung cancer (NSCLC) cancer and an ECOG PS 0-3
    Rajdev, L.
    Camacho, F.
    Hall, C.
    Hopkins, U.
    Gucalp, R.
    Perez-Soler, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
    Appleman, Leonard Joseph
    Puligandla, Maneka
    Pal, Sumanta K.
    Harris, Wayne
    Agarwal, Neeraj
    Costello, Brian Addis
    Ryan, Christopher W.
    Pins, Michael
    Kolesar, Jill
    Vaena, Daniel A.
    Parikh, Rahul Atul
    Hashmi, Mehmood
    Dutcher, Janice P.
    DiPaola, Robert S.
    Haas, Naomi B.
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Lilenbaum, R
    Rubin, M
    Samuel, J
    Boros, L
    Chidiac, T
    Seigel, L
    Graham, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 630S - 630S
  • [26] Randomized phase II study of pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) versus pem alone in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Li, Tianhong
    Piperdi, Bilal
    Walsh, William Vincent
    Kim, Mimi
    Gucalp, Rasim
    Haigentz, Missak
    Bathini, Venu Gopal
    Wu, Xiaoxia
    Pasquinelli, Patricia
    Gajavelli, Srikanth
    Sreedhara, Meera
    Beckett, Laurel A.
    Lara, Primo
    Gandara, David R.
    Perez-Soler, Roman
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)
    Shin-ichi Fukumoto
    Satoshi Oizumi
    Masao Harada
    Noriaki Sukoh
    Kosuke Nakano
    Satoshi Fuke
    Jun Sakakibara-Konishi
    Kei Takamura
    Kenichiro Ito
    Yuka Fujita
    Yutaka Nishigaki
    Toshiyuki Harada
    Kenji Akie
    Ichiro Kinoshita
    Toraji Amano
    Hiroshi Isobe
    Hirotoshi Dosaka-Akita
    Masaharu Nishimura
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 117 - 127
  • [28] A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)
    Fukumoto, Shin-ichi
    Oizumi, Satoshi
    Harada, Masao
    Sukoh, Noriaki
    Nakano, Kosuke
    Fuke, Satoshi
    Sakakibara-Konishi, Jun
    Takamura, Kei
    Ito, Kenichiro
    Fujita, Yuka
    Nishigaki, Yutaka
    Harada, Toshiyuki
    Akie, Kenji
    Kinoshita, Ichiro
    Amano, Toraji
    Isobe, Hiroshi
    Dosaka-Akita, Hirotoshi
    Nishimura, Masaharu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 117 - 127
  • [29] A RANDOMIZED PHASE II TRIAL OF CISPLATIN PLUS GEMCITABINE VERSUS CARBOPLATIN PLUS GEMCITABINE IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER: HOKKAIDO LUNG CANCER CLINICAL STUDY GROUP TRIAL (HOT0703)
    Harada, T.
    Fukumoto, S.
    Harada, M.
    Nakano, K.
    Sukoh, N.
    Fuke, S.
    Asahina, H.
    Takamura, K.
    Yamamoto, M.
    Fujita, Y.
    Akie, K.
    Kinoshita, I.
    Oizumi, S.
    Akita, H.
    Isobe, H.
    Nishimura, M.
    ANNALS OF ONCOLOGY, 2014, 25
  • [30] Randomized Phase II Trial of Gemcitabine and Carboplatin (G/C) With or Without Dexamethasone (Dex) Pretreatment in Chemotherapy-naive Patients (pts) With Advanced Non-small Cell Lung Cancer (NSCLC) - Results of Kyoto Thoracic Oncology Research Group (KTORG) Trial 0501
    Yoshioka, H.
    Mio, T.
    Nakatani, K.
    Hirabayashi, M.
    Yokoyama, T.
    Iwasaku, M.
    Kim, Y. H.
    Taguchi, Y.
    Ishida, T.
    Mishima, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S625 - S625
12345